Core Insights - Boston Scientific has agreed to acquire Nalu Medical for $533 million, valuing the company at $600 million, to enhance its neuromodulation portfolio targeting chronic peripheral nerve pain [8] - The acquisition aligns with Boston Scientific's strategy of expanding through tuck-in deals and private investments [8] - Nalu's neurostimulation system, which received FDA clearance in 2019, is designed to alleviate pain in areas such as the shoulder, lower back, and knee [3][8] Financial Projections - Nalu is projected to generate over $60 million in sales by 2025, with an expected sales increase of more than 25% in 2026 [5] - The transaction is anticipated to have an immaterial impact on adjusted earnings per share in 2026, becoming slightly accretive in 2027 and increasingly accretive thereafter [5] Strategic Focus - Boston Scientific has completed over 40 acquisitions in the past decade and maintains approximately 45 active investments in its venture capital portfolio [4] - The company is expected to prioritize mergers and acquisitions as a key component of its capital allocation strategy to maintain category leadership [5]